Business

Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York

Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York.

Nektar TherapeuticsMay 27, 20262
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York

About this update from Nektar Therapeutics

SAN FRANCISCO , May 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York. The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website:  https://ir.nektar.com/events-and-presentations/events . A replay of the fireside chat will be available for 30 days. If you would like to request a one-on-one meeting with company management during the conference, please reach out to your respective representative. About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar is headquartered in San Francisco, California. For further information, visit  www.nektar.com  and follow us on LinkedIn. Contacts For Investors: Vivian Wu 628-895-0661 [email protected] Corey Davis, Ph.D. LifeSci Advisors 212-915-2577 [email protected] For Media: Susan Roberts LifeSci Communications 202-779-0929 [email protected] View original content to download multimedia: https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference-in-new-york-302783711.html

View stock analysis, news, and events for Nektar Therapeutics

Nektar TherapeuticsJefferies Global Healthcare Conferencecompany managementwebcast linkfireside chat

More from Nektar Therapeutics

All Nektar Therapeutics news →